U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07658898) titled 'dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia' on June 08.
Brief Summary: This randomized, double-blind, sham-controlled trial aims to evaluate the efficacy and safety of dorsal anterior cingulate cortex-targeted temporal interference stimulation in individuals with schizophrenia. Participants will be randomly assigned to receive either active or sham stimulation for 10 sessions over two consecutive weeks. The primary outcome is the change in negative symptoms, assessed using the Negative Symptom Subscale of the Positive and Negative Syndrome Scale. Cognitive performance, detailed dimension...